SIGN updates its guideline on the management of migraine

Abstract

The Scottish Intercollegiate Guidelines Network (SIGN) has recently updated its guideline on the pharmacological management of migraine (SIGN 155) to include new information on the use of anti‐CGRP monoclonal antibodies. This article provides a round‐up of the main changes to the guidance.